

# Drug dependence associated with triptans and ergot derivatives: a case/non-case study

Frédérique Beau-Salinas · Annie Pierre Jonville-Béra ·  
Haware Cissoko · Lamiae Bensouda-Grimaldi ·  
Elisabeth Autret-Leca

Received: 2 December 2008 / Accepted: 23 November 2009  
© Springer-Verlag 2009

## Abstract

**Introduction** The aim of this case/non-case study was to assess and compare the risk of drug dependence associated with different migraine-specific drugs, i.e., ergot derivatives and triptans, using the French pharmacovigilance database. **Methods** Reports on drug side effects recorded in this database between January 1985 and June 2007 were analyzed, and triptans (almotriptan, eletriptan, naratriptan, sumatriptan, and zolmitriptan) as well as ergot derivatives used in acute migraine were examined. For all reports, cases were defined as those reports corresponding to “drug abuse,” “physical or mental drug dependence,” and “pharmacodependence,” whereas “non-cases” were defined as all the remaining SED reports. The method’s reliability was assessed by calculating the risk associated with a negative (amoxicillin) and a positive (benzodiazepines) control. The risk of dependence associated with each drug

and control was evaluated by calculating the odds ratio (OR) with a confidence interval of 95%.

**Results** Among the 309,178 reports recorded in the database, drug dependence accounted for 0.8% (2,489) of the reports, with 10.9% (449) involving a triptan, and 9.33% (332) an ergot derivative. The risk of dependence was similar for triptans and ergot derivatives and did not differ from that of benzodiazepines. In the triptan group, the risk (odds ratio [95% CI]) ranged from 10.3 [4.8–22.3] for sumatriptan to 21.5 for eletriptan [10.1–45.6], while in the ergot derivative group, it ranged from 12 [8–17.9] for ergotamine to 20.6 [8–53] for dihydroergotamine.

**Conclusions** These findings confirm the hypothesis that triptans and ergot derivatives are associated with an increased risk of drug dependence.

**Keywords** Migraine treatment · Medication overuse · Drug dependence · Triptans · Ergot derivatives · Case/non-case study

F. Beau-Salinas · A. P. Jonville-Béra · H. Cissoko ·  
L. Bensouda-Grimaldi · E. Autret-Leca  
Department of Pharmacology, CHRU of Tours,  
Bretonneau Hospital, Regional Centre of Pharmacovigilance,  
2 boulevard Tonnellé,  
37 044 Tours Cedex 9, France

L. Bensouda-Grimaldi · E. Autret-Leca  
Department of Pharmacology, François Rabelais University  
of Tours, Regional Centre of Pharmacovigilance,  
2 boulevard Tonnellé,  
37 044 Tours Cedex 9, France

F. Beau-Salinas (✉)  
Service de Pharmacologie Clinique, CHRU de Tours,  
Bâtiment B2A-2 boulevard Tonnellé,  
37044 Tours Cedex 9, France  
e-mail: f.beau-salinas@chu-tours.fr

## Introduction

Acute migraine affects about 11% of the Caucasian population [1], and it is treated with common analgesics or specific drugs, such as ergot derivatives and the more recently available triptans [1]. Medication-overuse (MO) has been associated with the use of analgesics, opioids [2–4], ergot derivatives [5], and more recently, with triptans [2, 3, 6–10]. MO is a secondary cause of chronic daily headache occurring in 4% of the population worldwide [11] and 3% of the French population [12]. Medication-overuse headache (MOH) is defined by the following criteria: headache present at least 15 days a month, regular intake ( $\geq 10$  days per month for  $>3$  months) of one or more anti-

migraine drugs, occurrence or worsening of headache during medication overuse, and reversion to the previous pattern within 2 months after discontinuation of the over-used medication [13]. MOH, whose physiological mechanism is suggested to be similar to that of drug addiction [14, 15], is mentioned in the summary of product characteristics for anti-migraine drugs as “headache secondary to excessive use,” “daily chronic headache secondary to excessive use,” or “headache or rebound secondary to chronic use.” MOH has been associated with the use of opioids, ergot derivatives, and triptans [2–4]. Case reports pertaining to MOH were published shortly after the launch of sumatriptan [9, 16], naratriptan, eletriptan, and zolmitriptan [10, 17]. MOH may share characteristics with drug dependence [9]; the latter is defined [18] as a maladaptive pattern of substance use, leading to clinically significant impairment or distress manifested by one or more of seven criteria (Table 1). Several of these criteria, i.e., tolerance, withdrawal, and overuse (“taking the substance often in larger amounts or over a longer period than was intended”), are closely related to those of MOH. In an observational study involving 1,861 patients with chronic daily headache, 48% were identified as MOH patients, and among these, 68% met drug dependence criteria [19].

No epidemiological study so far has compared the different migraine-specific drugs in terms of drug dependence risk using a case/non-case study design.

## Aim

The aim of our study was to assess and compare the risk of drug dependence associated with different classes of anti-migraine drugs.

## Methods

A case/non-case study design was used, based on the side effects of drugs (SED) recorded in the French pharmacovigilance database.

Since 1985, all SED reports sent spontaneously by health professionals, but not manufacturers, to 1 of the 31 French Regional Pharmacovigilance Centers have been entered into this database. Before being recorded in the database, each SED report is reviewed by medically qualified personnel at the center. Irrespective of their severity, all SEDs recorded in the French pharmacovigilance database from January 1, 1985, to June 17, 2007, were included in the analysis. *Cases* were defined as SED reports that contained at least one term indicative of drug dependence according to the database’s glossary, i.e., “physical drug dependence,” “mental drug dependence,” “pharmacodependence,” or “drug abuse.” Although MOH did not exist in the database’s glossary, “drug abuse” was deemed to be a close description of MOH. *Non-cases* (controls) were all the remaining SED reports recorded in the database. Exposure to one of the study drugs was defined as an SED report where one of the study drugs was mentioned and had the highest imputability score. Because of the potential occurrence of multiple SEDs within the same report, one patient could appear in both cases and non-cases. However, since the case group was very small compared to the non-case group, the impact was not considered significant.

Case/non-case studies [20, 21] based on database data rely on principles similar to case/control studies. This method may be used to generate signals from a pharmacovigilance database [21, 22]. It is based on the principle that the number of SED reports recorded with all drugs remains

**Table 1** Diagnostic criteria for substance dependence. Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV)

### Criteria

Tolerance, as defined by either of the following:

The need for markedly increased amounts of the substance to achieve intoxication or desired effect

Markedly diminished effect with continuous use of the same amount of the substance

Withdrawal, as manifested by either of the following:

The characteristic withdrawal syndrome for the substance

The same (or closely related) substance is taken to relieve or avoid withdrawal symptoms

Taking the substance often in large amounts or over a longer period than was intended

A persistent desire or unsuccessful efforts to cut down or control substance use

Spending a great deal of time in activities necessary to obtain or use the substance or to recover from its effects

Giving up social, occupational, or recreational activities because of substance use

Continuing the substance use with the knowledge that it is causing or exacerbating a persistent or recurrent physical or psychological problem

The DSM IV defines the diagnostic criteria for substance dependence as a maladaptive pattern of substance use, leading to clinically significant impairment or distress, as manifested by one or more of the above, occurring within a 12-month period

**Table 2** Risk of drug dependence associated with triptans, ergot derivatives, benzodiazepines, and amoxicillin

	All adverse events (a+c)	Drug dependence (a)	OR [95% CI]
Triptans	449	49 (10.9%)	15.38 [11.4–20.74]
Zolmitriptan	212	23	15.2 [9.8–23.4]
Sumatriptan	91	7	10.3 [4.8–22.3]
Naratriptan	84	10	16.7 [8.6–32.4]
Eletriptan	54	8	21.5 [10.1–45.6]
Almotriptan	8	1	17.61 [2.2–143.2]
Ergot derivatives	332	31 (9.33%)	12.84 [8.85–18.62]
Ergotamine	297	26	12 [8–17.9]
Dihydroergotamine	35	5	20.6 [8–53]
Benzodiazepines	11,093	649 (5.8%)	10 [9.13–10.96]
Amoxicillin	17,311	1 (0.005%)	0.01 [0–0.5]

*a* Drug dependence adverse events associated with the study drug, *a+c* all adverse events associated with the study drug, *OR* odds ratio

constant over time although the proportion of a given SED recorded with a specific drug may exceed the expected value. The association between drug exposure and SED was assessed by calculating the relative risk (RR), also called proportional reporting ratio [20, 21]. As the number of drug dependence cases is much lower than the total number of SED reports recorded in the database, the relative risk may be evaluated by calculating the odds ratio (OR).

The study drugs were those labeled in France for migraine attacks: triptans, i.e., almotriptan, eletriptan, naratriptan, sumatriptan, and zolmitriptan; and ergot derivatives, i.e., oral ergotamine and inhaled or injectable dihydroergotamine. The reliability of the method was assessed by calculating the risk associated with a negative control (amoxicillin, which has never been linked to drug dependence) and a positive control (benzodiazepines, for which the risk of drug dependence is well established) [23].

For the analysis, the total number of SEDs irrespective of the drug used (*n*) and the number of drug dependences associated with all drugs (*a+b*) were assessed. For each study drug, the number of drug dependences associated with the study drug (*a*), the number of drug dependences associated with all drugs except the study drug (*b*), the number of SEDs other than drug dependence associated with the study drug (*c*), the number of SEDs other than drug dependence associated with all drugs except the study drug (*d*), and the total number of SEDs associated with the study drug (*a+c*) were assessed.

This data was either obtained directly from the database (*n*, *a*, *a+b*, *a+c*) or calculated (*b*, *c*, *d*).<sup>1</sup> The risk of drug dependence for each anti-migraine drug and each control (amoxicillin and benzodiazepines) was determined by calculating the odds ratios ( $OR = ad/bc$ ) with 95% confidence intervals [21].

<sup>1</sup>  $b = (a + b) - a$ ;  $c = (a + c) - a$ ;  $d = n - (a + b) - c$

## Results

Among the 309,178 SED reports recorded in the French pharmacovigilance database from January 1, 1985, to June 17, 2007, 2,489 drug dependences were reported accounting for 0.8% of all reports. There were 449 SED reports involving triptans, with drug dependence occurring in 10.9% (49 reports), and 332 SED reports involving an ergot derivative, with drug dependence occurring in 9.33% (31 reports).

The risk of drug dependence was similar for triptans ( $OR = 15.38 [11.4–20.74]$ ) and ergot derivatives ( $OR = 12.84 [8.85–18.62]$ ), and for both drugs, the risk was found not to differ from that of benzodiazepines ( $OR = 10 [9.13–10.96]$ ). In contrast, the risk of drug dependence for amoxicillin was almost zero ( $OR = 0.1 [0–0.5]$ ). The drug dependence risk among the triptans ranged from 10.3 [4.8–22.3] for sumatriptan to 21.5 [10.1–45.6] for eletriptan, and among the ergot derivatives from 12 [8–17.9] for ergotamine to 20.6 [8–53] for dihydroergotamine (Table 2). The accuracy of the result for almotriptan is limited since there was only one report of drug dependence associated with this drug.

## Discussion

Our results indicate that the use of ergot derivatives and triptans was associated with a risk of drug dependence.

To our knowledge, the present study is the first of its kind to use a case/non-case design to estimate the risk of drug dependence. For the purpose of our study, this method was deemed reliable for analyzing drug dependence because we found no particular risk associated with amoxicillin (negative control) but a high risk associated with benzodiazepines (positive control). The case/non-case design is a suitable method for conducting internal comparisons to detect associations between specific SEDs and drug exposures. The method is simple, quick, and

cheap, and uses data already available. The problems associated with the recruitment of controls for case/control studies do not apply to case/non-case studies, for all reports not identified as cases are non-cases. Several studies using the case/non-case method have been published on this database applying to different fields of drug safety [24–26]. One limitation of the pharmacovigilance database and consequently of the case/non-case method [20, 26] lies in the selection and notoriety bias due to the spontaneous notification system, which depends on the cooperation and goodwill of healthcare professionals [25–28]. The association between a given drug and an SED may be artificially decreased if another specific SED is more often reported (and inversely, the association may be increased if there are only a few other SEDs associated with the study drug). Finally, if several drugs that are likely to induce a specific SED are used concomitantly, this SED may be observed among both cases and non-cases [26]. However, since concomitant use of triptans and ergot derivatives is contraindicated, this bias is unlikely to have occurred in our study.

The results of the present paper using the case/non-case method confirm that the use of ergot derivatives and triptans was associated with a risk of drug dependence. Previous studies have assessed MOH or headache recurrence more often than drug dependence, and the incidence of overuse more often than its risk. In one study of 1,720 triptan consumers, 4% used these drugs more than 10 times a week [29], and in another study of 20,686 triptan consumers, 1.9% took them more than 12 times a month [30]. In a French study, 8% of 301 patients treated with triptans reimbursed by the national health insurance system took these drugs more than 12 times a month [31], and hence could be considered to be overusers. Data from 53 trials [32] involving triptans suggested that the risk of headache recurrence might be lower for frovatriptan, naratriptan, and eletriptan, which display a longer half-life than the other available triptans. As headache recurrence promotes drug overuse, which is a risk factor for drug dependence, it may be hypothesized that the risk of drug dependence might be lower for these three drugs. However, our data cannot be used to support this theory linking dependence to triptans to their respective half-lives, since the 95% intervals were very large and overlapped.

A few other studies have addressed the issue of dependence to acute migraine treatments. A marked need for a substance, similar to that which addicts experience for drugs, has been observed in chronic daily headache patients overusing analgesics [33]. The authors hypothesize that this dependence is not due to the addictive properties of analgesics, but to their capacity to alleviate the patient's suffering in spite of daily headache. In a series of patients suffering from probable MOH in Taiwan, 68% of the subjects met the criteria of substance dependence [19], with

most of them (80%) overusing ergotamine. In a multicenter, cross-sectional, observational study conducted in France, 66.8% of MOH patients were considered dependent on acute headache treatments according to DSM IV criteria [34]. A significantly higher number of dependent versus non-dependent MOH patients were found to have overused opiate-containing acute headache treatments, and both dependent and non-dependent MOH patients (with no statistical difference found between both groups) often overused triptans, whereas only a few of them overused ergotamine. In another publication, 60% of the subjects suffering from pure triptan-overuse headache fulfilled criteria of drug dependence compared to 79% of those suffering from combined (triptan and other anti-migraine drugs) overuse headache [35].

In our analysis, no difference was found between triptans and ergot derivatives concerning risk of drug dependence, although some authors previously observed that with ergotamine overuse, there was lower incidence [5], a more rapid occurrence (1.7 vs 2.7 years) [13, 36], a lower monthly intake frequency [36], and a shorter time to recovery upon treatment cessation (5 vs. 10 days) [37] than with triptan overuse. This discrepancy in results may be accounted for by the longer observation period (1985–2007) of the current study. In fact, a decrease in ergotamine overuse was noted since triptans were launched on the market. In the United States, ergotamine overuse decreased from 19% in 1990 to 0% in 2005, whereas triptan overuse increased from 0% to 22% during the same time period [38].

## Conclusion

Our findings support the hypothesis that triptans and ergot derivatives are associated with an increased risk of drug dependence. The study results also demonstrate the usefulness of applying the case/non-case method to a large pharmacovigilance database to reveal a link between a given drug and a side effect as guidance for confirmatory prospective studies.

**Acknowledgments** We wish to thank the 31 centers of the French Pharmacovigilance System for providing data.

## References

1. Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine—current understanding and treatment. *N Engl J Med* 346:257–270
2. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V (2001) Clinical features of withdrawal headache following overuse of triptans and other headache drugs. *Neurology* 57:1694–1698

3. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC (2002) Features of medication overuse headache following overuse of different acute headache drugs. *Neurology* 59:1011–1014
4. Silberstein SD, Liu D (2002) Drug overuse and rebound headache. *Curr Pain Headache Rep* 6:240–247
5. Evers S, Gralow I, Bauer B, Suhr B, Buchheister A, Husstedt IW, Ringelstein EB (1999) Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. *Clin Neuropharmacol* 22:201–206
6. Gaist D, Tsiropoulos I, Sindrup SH, Hallas J, Rasmussen BK, Kragstrup J, Gram LF (1998) Inappropriate use of sumatriptan: population-based register and interview study. *BMJ* 316:1352–1353
7. Gaist D (1999) Use and overuse of sumatriptan. *Pharmacoepidemiological studies based on prescription register and interview data*. *Cephalgia* 19:735–761
8. Dowson A (1999) Drug-induced headaches. *Lancet* 354:254–255
9. Osborne MJ, Austin RCT, Dawson KJ, Lange L (1994) Drug points: is there a problem with long term use of sumatriptan in acute migraine? *BMJ* 308:113
10. Goadsby PJ (1998) Sumatriptan is not the only analgesic used inappropriately. *BMJ* 317:1016
11. Silberstein SD (2005) Chronic daily headache. *J Am Osteopath Assoc* 105:23S–29S
12. Lantéri-Minet P, Auray JP, el Hasnaoui A, Dartigues JF, Duru G, Henry P, Lucas C, Pradalier A, Chazot G, Gaudin AF (2003) Prevalence and description of chronic daily headache in the general population in France. *Pain* 102:143–149
13. Silberstein SB, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJA, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Steiner TJ (2005) The international classification of headache disorders, 2nd edition (ICHD-II) - revision of criteria for 8.2 medication-overuse headache. *Cephalgia* 25:460–465
14. Calabresi P, Cupini LM (2005) Medication-overuse headache: similarities with drug addiction. *Trends Pharmacol Sci* 26:62–68
15. Radat F, Créac'h C, Swendsen JD, Lafittau M, Irachabal S, Dousset V, Henry P (2005) Psychiatric comorbidity in the evolution from migraine to medication overuse headache. *Cephalgia* 25:519–522
16. Kaube H, May A, Diener HC (1994) Sumatriptan. *BMJ* 308:1573–1574
17. Limmroth V, Kazarawa Z, Fritsche G, Diener HC (1999) Headache after frequent use of serotonin agonists zolmitriptan and naratriptan. *Lancet* 353:378
18. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington DC
19. Fuh JL, Wang SJ, Lu SR, Juang KD (2005) Does medication overuse headache represent a behavior of dependence? *Pain* 119:49–55
20. Hauben M, Zhou X (2003) Quantitative methods in pharmacovigilance: focus on signal detection. *Drug Saf* 26:159–186
21. Evans SJW, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. *Pharmacoepidemiol Drug Saf* 10:483–486
22. Meyboom RHB, Egberts ACG, Edwards IR, Hekster YA, de Koning FHP, Gribnau FWJ (1997) Principles of signal detection in pharmacovigilance. *Drug Saf* 16:355–365
23. Schweizer E, Rickels K (1998) Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. *Acta Psychiatr Scand* 393(Suppl):95–101
24. Liautard C, Correa Nunes AM, Vial T, Chatillon F, Guy C, Ollagnier M, Descotes J (2002) Low-molecular weight heparins and thrombocytosis. *Ann Pharmacother* 36:1351–1354
25. Bareille MP, Montastruc JL, Lapeyre-Mestre M (2001) Atteintes hépatiques et médicaments anti-inflammatoires non stéroïdiens: étude cas/non cas dans la banque Nationale de Pharmacovigilance. *Thérapie* 56:51–55
26. Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, Bégaud B (1997) Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. *Br J Clin Pharmacol* 44:513–518
27. Desboeuf K, Lapeyre-Mestre M, Montastruc JL (1998) Risk of gastrointestinal haemorrhage with calcium antagonists. *Br J Clin Pharmacol* 46:87–89
28. Petit A, Piednoir D, Germain ML, Trenque T (2003) Hyperprolactinémies d'origine médicamenteuse: étude cas/non-cas dans la banque nationale de pharmacovigilance. *Thérapie* 58:159–163
29. Ottervanger JP, Valkenburg HA, Grobbee DE, Stricker BHC (1996) Pattern of sumatriptan use and overuse in general practice. *Eur J Clin Pharmacol* 50:353–355
30. Pearnau P, Vuillemet F, Schick J, Weill G (2006) Modes de prescription et de consommation des triptans en Alsace: un mésusage fréquent mais évitable. *Rev Neurol* 162:347–357
31. Roussel H, Lo Re G, Honorat C, Alonso M, Sciortino V (2006) Prescription des triptans en médecine de ville dans la région Midi-Pyrénées: indications, contre-indications, abus médicamenteux. *Thérapie* 61:507–516
32. Géraud G, Keywood C, Senard JM (2003) Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. *Headache* 43:376–388
33. Ferrari A, Cicero AF, Bertolini A, Leone S, Pasciullo G, Sternieri E (2006) Need for analgesics/drugs of abuse: a comparison between headache patients and addicts by the Leeds Dependence Questionnaire (LDQ). *Cephalgia* 26:187–193
34. Radat F, Créac'h C, Guegan-Massardier E, Mick G, Guy N, Fabre N, Giraud P, Nachit-Ouinekh F, Lantéri-Minet M (2008) Behavioral dependence in patients with medication overuse headache: a cross-sectional study in consulting patients using the DSM-IV criteria. *Headache* 48:1026–1036
35. Créac'h C, Radat F, Mick G, Guegan-Massardier E, Giraud P, Guy N, Fabre N, Nachit-Ouinekh F, Lantéri-Minet M (2009) One or several types of triptan overuse headaches? *Headache* 49:519–528
36. Katsarava Z, Diener HC, Limmroth V (2001) Medication overuse headache. A focus on analgesics, ergot alkaloids and triptans. *Drug Saf* 24:921–927
37. Relja G, Granato A, Bratina A, Antonello RM, Zorzon M (2006) Outcome of medication overuse headache after abrupt in-patient withdrawal. *Cephalgia* 26:589–595
38. Meskunas CA, Tepper J, Rapoport AM, Sheftell FD, Bigal ME (2006) Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. *Headache* 46:766–772